Inhibition of microRNA-34a mediates protection of thymosin beta 4 in endothelial progenitor cells against advanced glycation endproducts by targeting B-cell lymphoma 2.

Chen Q, Shen Z, Mao Y, Li Q, Liu Y, Mei M, Qiu F, Wang M

Canadian journal of physiology and pharmacology9 Aug 2019Cited by 5 (Europe PMC)

PMID31397599DOI10.1139/cjpp-2018-0743PepBankPUB-31397599

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. No result from this study comes from people.

01LabIn vitro (cells)Efficacy outcome
In endothelial progenitor cells exposed to advanced glycation endproducts, thymosin beta‑4 enhanced cell viability.
In plain wordsIn cells exposed to damaging sugar products, thymosin beta‑4 improved cell survival.
Peptide
Thymosin beta-4 (human)
Outcome
IncreaseCell viability
Study
n: not reported in source
Endothelial progenitor cells exposed to advanced glycation endproducts (AGEs)
Comparator
AGE-exposed cells without Tβ4
Outcome group
Cell viability and death · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
Treatment with thymosin beta 4 or transfection with microRNA-34a inhibitor enhanced cell viability, reduced apoptosis, abated oxidative stress, and attenuated mitochondrial dysfunction in endothelial progenitor cells exposed to advanced glycation endproducts.
1 context sentence(design, population, supporting numbers)
Summary · context
The aim of our work was to test whether thymosin beta 4 protected endothelial progenitor cells against apoptosis induced by advanced glycation endproducts and investigate the underlying mechanism.
Report a problemFND-3139759901
02LabIn vitro (cells)Efficacy outcome
In endothelial progenitor cells exposed to advanced glycation endproducts, thymosin beta‑4 reduced apoptosis.
In plain wordsIn cells exposed to damaging sugar products, thymosin beta‑4 reduced programmed cell death.
Peptide
Thymosin beta-4 (human)
Outcome
DecreaseApoptosis
Study
n: not reported in source
Endothelial progenitor cells exposed to advanced glycation endproducts (AGEs)
Comparator
AGE-exposed cells without Tβ4
Outcome group
Cell viability and death · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
Treatment with thymosin beta 4 or transfection with microRNA-34a inhibitor enhanced cell viability, reduced apoptosis, abated oxidative stress, and attenuated mitochondrial dysfunction in endothelial progenitor cells exposed to advanced glycation endproducts.
1 context sentence(design, population, supporting numbers)
Summary · context
The aim of our work was to test whether thymosin beta 4 protected endothelial progenitor cells against apoptosis induced by advanced glycation endproducts and investigate the underlying mechanism.
Report a problemFND-3139759902
03LabIn vitro (cells)Efficacy outcome
In endothelial progenitor cells exposed to advanced glycation endproducts, thymosin beta‑4 abated oxidative stress.
In plain wordsIn cells exposed to damaging sugar products, thymosin beta‑4 lowered oxidative stress.
Peptide
Thymosin beta-4 (human)
Outcome
DecreaseOxidative stress
Study
n: not reported in source
Endothelial progenitor cells exposed to advanced glycation endproducts (AGEs)
Comparator
AGE-exposed cells without Tβ4
Outcome group
Oxidative stress · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
Treatment with thymosin beta 4 or transfection with microRNA-34a inhibitor enhanced cell viability, reduced apoptosis, abated oxidative stress, and attenuated mitochondrial dysfunction in endothelial progenitor cells exposed to advanced glycation endproducts.
1 context sentence(design, population, supporting numbers)
Summary · context
The aim of our work was to test whether thymosin beta 4 protected endothelial progenitor cells against apoptosis induced by advanced glycation endproducts and investigate the underlying mechanism.
Report a problemFND-3139759903
04LabIn vitro (cells)Efficacy outcome
In endothelial progenitor cells exposed to advanced glycation endproducts, thymosin beta‑4 attenuated mitochondrial dysfunction.
In plain wordsIn cells exposed to damaging sugar products, thymosin beta‑4 reduced mitochondrial damage.
Peptide
Thymosin beta-4 (human)
Outcome
DecreaseMitochondrial dysfunction
Study
n: not reported in source
Endothelial progenitor cells exposed to advanced glycation endproducts (AGEs)
Comparator
AGE-exposed cells without Tβ4
Outcome group
Mitochondrial function · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
Treatment with thymosin beta 4 or transfection with microRNA-34a inhibitor enhanced cell viability, reduced apoptosis, abated oxidative stress, and attenuated mitochondrial dysfunction in endothelial progenitor cells exposed to advanced glycation endproducts.
1 context sentence(design, population, supporting numbers)
Summary · context
The aim of our work was to test whether thymosin beta 4 protected endothelial progenitor cells against apoptosis induced by advanced glycation endproducts and investigate the underlying mechanism.
Report a problemFND-3139759904
05LabIn vitro (cells)Mechanism
In endothelial progenitor cells, advanced glycation endproducts raised microRNA-34a levels and thymosin beta‑4 treatment attenuated this rise.
In plain wordsIn cells exposed to damaging sugar products, thymosin beta‑4 lowered the rise in a small regulatory RNA called microRNA-34a.
Peptide
Thymosin beta-4 (human)
Outcome
DecreasemicroRNA-34a level
Study
n: not reported in source
Endothelial progenitor cells exposed to advanced glycation endproducts (AGEs)
Comparator
AGE-exposed cells without Tβ4
Outcome group
Receptor activity and mechanism · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
Incubation with advanced glycation endproducts led to increased levels of microRNA-34a, which was attenuated by treatment with thymosin beta 4.
1 context sentence(design, population, supporting numbers)
Summary · context
The aim of our work was to test whether thymosin beta 4 protected endothelial progenitor cells against apoptosis induced by advanced glycation endproducts and investigate the underlying mechanism.
Report a problemFND-3139759905
06LabIn vitro (cells)Mechanism
Transfection with microRNA-34a reversed the protective effect of thymosin beta‑4 against advanced glycation endproduct injury in endothelial progenitor cells.
In plain wordsIn cells, adding extra microRNA-34a reversed the protection that thymosin beta‑4 gave against damaging sugar products.
Peptide
Thymosin beta-4 (human)
Outcome
DecreaseProtection by Tβ4 after microRNA-34a transfection
Study
n: not reported in source
Endothelial progenitor cells exposed to advanced glycation endproducts (AGEs)
Comparator
Tβ4 without microRNA-34a transfection
Outcome group
Cell viability and death · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
Transfection with microRNA-34a reversed the beneficial effect of thymosin beta 4 against injuries induced by advanced glycation endproducts.
1 context sentence(design, population, supporting numbers)
Summary · context
The aim of our work was to test whether thymosin beta 4 protected endothelial progenitor cells against apoptosis induced by advanced glycation endproducts and investigate the underlying mechanism.
Report a problemFND-3139759906
07LabIn vitro (cells)Mechanism
In endothelial progenitor cells exposed to advanced glycation endproducts, thymosin beta‑4 treatment upregulated B-cell lymphoma 2 expression.
In plain wordsIn cells exposed to damaging sugar products, thymosin beta‑4 raised the level of the protective protein B-cell lymphoma 2.
Peptide
Thymosin beta-4 (human)
Outcome
IncreaseB-cell lymphoma 2 expression
Study
n: not reported in source
Endothelial progenitor cells exposed to advanced glycation endproducts (AGEs)
Comparator
AGE-exposed cells without Tβ4
Outcome group
Receptor activity and mechanism · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
thymosin beta 4 treatment upregulated B-cell lymphoma 2 expression in endothelial progenitor cells exposed to advanced glycation endproducts.
1 context sentence(design, population, supporting numbers)
Summary · context
The aim of our work was to test whether thymosin beta 4 protected endothelial progenitor cells against apoptosis induced by advanced glycation endproducts and investigate the underlying mechanism.
Report a problemFND-3139759907
08LabIn vitro (cells)Mechanism
Knockdown of B-cell lymphoma 2 abolished the protection of thymosin beta‑4 against advanced glycation endproducts in endothelial progenitor cells.
In plain wordsIn cells, removing the protein B-cell lymphoma 2 abolished the protection that thymosin beta‑4 gave against damaging sugar products.
Peptide
Thymosin beta-4 (human)
Outcome
DecreaseProtection by Tβ4 after B-cell lymphoma 2 knockdown
Study
n: not reported in source
Endothelial progenitor cells exposed to advanced glycation endproducts (AGEs)
Comparator
Tβ4 without B-cell lymphoma 2 knockdown
Outcome group
Cell viability and death · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
More importantly, knockdown of B-cell lymphoma 2 abolished the protection of thymosin beta 4 and microRNA-34a inhibitor against advanced glycation endproducts.
1 context sentence(design, population, supporting numbers)
Summary · context
The aim of our work was to test whether thymosin beta 4 protected endothelial progenitor cells against apoptosis induced by advanced glycation endproducts and investigate the underlying mechanism.
Report a problemFND-3139759908

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
13 Oct 2026, 01:52 UTC
Study results updated
Version 1
12 Oct 2026, 18:17 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.

Inhibition of microRNA-34a mediates protection of thymosin beta 4 in endothelial progenitor cells against advanced glycation endproducts by targeting B-cell lymphoma 2.

Summary

Results from this study8

Version history

Subjects

Publication types

MeSH terms

Keywords